Dr. Khalil is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
619 19th St S
Birmingham, AL 35249Phone+1 205-934-4011
Education & Training
- University at BuffaloFellowship, Hematology and Medical Oncology, 2017 - 2020
- HCA Florida JFK Hospital/University of Miami Miller School of Medicine GME ConsortiumResidency, Internal Medicine, 2014 - 2017
- American University of Beirut Faculty of MedicineClass of 2012
Certifications & Licensure
- AL State Medical License 2020 - 2024
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Ramucirumab Plus Pembrolizumab vs Usual Care for Treatment of Stage IV or Recurrent Non-Small Cell Lung Cancer Following Immunotherapy, Pragmatica-Lung Study Start of enrollment: 2023 Mar 14
- Study With Immunotherapy Combinations in Participants With Metastatic Non-Small Cell Lung Cancer Start of enrollment: 2023 Feb 01
Publications & Presentations
PubMed
- 220 citationsNeoadjuvant-Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma.Sapna P Patel, Megan Othus, Yuanbin Chen, G Paul Wright Jr, Kathleen J Yost
The New England Journal of Medicine. 2023-03-02 - 65 citationsNext generation sequencing of PD-L1 for predicting response to immune checkpoint inhibitorsJeffrey M. Conroy, Sarabjot Pabla, Mary Nesline, Sean T. Glenn, Antonios Papanicolau-Sengos
Journal for Immunotherapy of Cancer. 2019-01-24 - 1 citationsTalazoparib in Patients With Solid Tumors With/Mutation: Results From the Targeted Agent and Profiling Utilization Registry Study.Gordan Srkalovic, Michael Rothe, Pam K Mangat, Elizabeth Garrett-Mayer, Eugene R Ahn
JCO Precision Oncology. 2024-06-01
Press Mentions
- FDA Approvals Create “Difficult Decisions” in Early-Stage Resectable NSCLCAugust 26th, 2024
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: